VANECK VECTORS ETF TR's ticker is GDX and the CUSIP is 92189F106. A total of 701 filers reported holding VANECK VECTORS ETF TR in Q4 2021. The put-call ratio across all filers is 1.44 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $211,826 | -95.1% | 7,035 | -94.7% | 0.02% | -95.5% |
| Q1 2023 | $4,311,343 | +15.7% | 133,271 | +2.5% | 0.33% | +6.8% |
| Q4 2022 | $3,727,054 | +34.0% | 130,043 | +12.7% | 0.31% | +6.1% |
| Q3 2022 | $2,782,000 | +48.6% | 115,348 | +68.7% | 0.29% | +72.4% |
| Q2 2022 | $1,872,000 | -34.6% | 68,362 | -8.5% | 0.17% | -27.0% |
| Q1 2022 | $2,864,000 | +34.4% | 74,681 | +12.2% | 0.23% | +52.3% |
| Q4 2021 | $2,131,000 | -0.5% | 66,531 | -8.4% | 0.15% | -16.4% |
| Q3 2021 | $2,141,000 | +14.1% | 72,655 | +31.6% | 0.18% | +10.2% |
| Q2 2021 | $1,876,000 | +108.2% | 55,197 | +99.0% | 0.17% | +72.9% |
| Q1 2021 | $901,000 | +6.5% | 27,735 | +18.0% | 0.10% | -17.9% |
| Q4 2020 | $846,000 | -1.3% | 23,496 | +7.4% | 0.12% | -44.0% |
| Q3 2020 | $857,000 | +68.7% | 21,881 | +57.9% | 0.21% | +34.0% |
| Q2 2020 | $508,000 | -77.6% | 13,854 | -83.6% | 0.16% | -82.0% |
| Q3 2019 | $2,263,000 | – | 84,719 | – | 0.87% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 738,500 | $20,220,000 | 66.82% |
| Baymount Management LP | 145,000 | $3,970,000 | 28.08% |
| New Harbor Financial Group, LLC | 1,371,341 | $37,547,000 | 18.51% |
| New Harbor Financial Group, LLC | 1,291,700 | $35,366,000 | 17.44% |
| MKP Capital Management, L.L.C. | 1,500,000 | $41,070,000 | 13.74% |
| Windmill Hill Asset Management Ltd | 844,600 | $23,125,000 | 11.94% |
| Hollow Brook Wealth Management LLC | 768,567 | $21,043,000 | 11.57% |
| Grand Central Investment Group | 261,915 | $7,171,000 | 10.33% |
| Point72 Europe (London) LLP | 1,467,000 | $40,166,000 | 8.50% |
| Slate Path Capital LP | 4,600,000 | $125,948,000 | 7.87% |